NEUPRO (nda021829)- (1MG/24HR,2MG/24HR,3MG/24HR,4MG/24HR,6MG/24HR,8MG/24HR)

Generic Name	ROTIGOTINE	Innovator	UCB INC
Dosage	1MG/24HR,2MG/24HR,3MG/24HR,4MG/24HR,6MG/24HR,8MG/24HR
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2032-Mar-01	NCE Excl Expiry	2012-May-09
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	NEUPRO is a dopamine agonist indicated for the treatment of: • Parkinson’s disease • Moderate-to-severe primary Restless Legs Syndrome

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	1	0

Other Developers

Total Other Developers	8

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
1MG/24HR	**	**	Up	-	-
2MG/24HR	**	**	Up	-	-
3MG/24HR	**	**	Up	-	-
4MG/24HR	**	**	Up	-	-
6MG/24HR	**	**	Up	-	-
8MG/24HR	**	**	Up	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of NEUPRO